Helen Barr

Contact

• workRoom B35 Clinical Sciences Building
  Nottingham City Hospital
  Hucknall Road
  Nottingham
  NG5 1PB
  UK
• work07812269099
• Helen.Barr@nottingham.ac.uk

Research Summary

Nottingham Biomedical Research Center, Chronic infection stream

University of Nottingham collaborations: Gastro BRC, MRI, National Biofilms Institute

Expertise in respiratory medicine, particularly chronic lung diseases such as cystic fibrosis and non-CF bronchiectasis. Areas of specific expertise are translational research and clinical trials.

Research interests in quorum sensing, biomarkers, host response to infection, epidemiology and multi-morbidity in chronic disease

UK Cystic Fibrosis Clinical Trial Accelerator Platform Clinical Lead, Cystic Fibrosis Trust

UK principle investigator for FORMAT: Finding the Optimal Regimen for Mycobacterium Abscessus Treatment. Chief Investigator: Claire Wainwright, University of Queensland, Austrilia

Selected Publications

• BARR, H.L., BRITTON, J., SMYTH, A.R. and FOGARTY, A.W., 2011. Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study BMJ. 343(7821), d4662
• BARR HL, MACFARLANE JT, MACGREGOR O, FOXWELL R, BUSWELL V and LIM WS, 2008. Ethical Planning For An Influenza Pandemic. Clinical Medicine (London, England). 8(1), 49-52

• View all publications

Future Research

Development of point of care diagnostics for respiratory pathogens including Pseudomonas aeruginosa

Gastrointestinal symptoms in cystic fibrosis

Multimorbidity in cystic fibrosis

Clinical Trials

• BARR HL, HALLIDAY N, BARRETT DA, WILLIAMS P, FORRESTER DL, PECKHAM D, WILLIAMS K, SMYTH AR, HONEYBOURNE D, L WHITEHOUSE J, NASH EF, DEWAR J, CLAYTON A, KNOX AJ, CÁMARA M and FOGARTY AW, 2016. Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 16(2), 230-238
• DARCH, SOPHIE E., MCNALLY, ALAN, HARRISON, FREYA, CORANDER, JUKKA, BARR, HELEN L., PASZKIEWICZ, KONRAD, HOLDEN, STEPHEN, FOGARTY, ANDREW, CRUSZ, SHANIKA A. and DIGGLE, STEPHEN P., 2015. Recombination is a key driver of genomic and phenotypic diversity in a Pseudomonas aeruginosa population during cystic fibrosis infection SCIENTIFIC REPORTS. 5,
• SINGH, SONALI, BARR, HELEN, LIU, YI-CHIA, ROBINS, ADRIAN, HEEB, STEPHAN, WILLIAMS, PAUL, FOGARTY, ANDREW, CAMARA, MIGUEL and MARTINEZ-POMARES, LUISA, 2015. Granulocyte-Macrophage Colony Stimulatory Factor Enhances the Pro-Inflammatory Response of Interferon-gamma-Treated Macrophages to Pseudomonas aeruginosa Infection PLOS ONE. 10(2),
• BARR, H. L., HALLIDAY, N., CAMARA, M., BARRETT, D. A., WILLIAMS, P., FORRESTER, D. L., SIMMS, R., SMYTH, A. R., HONEYBOURNE, D., WHITEHOUSE, J. L., NASH, E. F., DEWAR, J., CLAYTON, A., KNOX, A. J. and FOGARTY, A. W., 2015. Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis: Eur Respir J Eur Respir J.
• FORRESTER DL, KNOX AJ, SMYTH AR, BARR HL, SIMMS R, PACEY SJ, PAVORD ID, HONEYBOURNE D, DEWAR J, CLAYTON A and FOGARTY AW, 2015. Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial. Pediatric pulmonology. 51(3), 253-7
• BARR, H. L., CAMARA, M., BARRETT, D., WILLIAMS, P., FORRESTER, D., HALLIDAY, N., SMYTH, A., HONEYBOURNE, D., WHITEHOUSE, J., NASH, E. F., DEWAR, J., CLAYTON, A., MCKEEVER, T., KNOX, A. and FOGARTY, A., 2014. FACTORS PREDICTING A SHORTER TIME TO NEXT PULMONARY EXACERBATION IN ADULTS WITH CYSTIC FIBROSIS PEDIATRIC PULMONOLOGY. 49, 326-327
• BARR, H.L., BRITTON, J., SMYTH, A.R. and FOGARTY, A.W., 2011. Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study BMJ. 343(7821), d4662
• BARR HL, MACFARLANE JT, MACGREGOR O, FOXWELL R, BUSWELL V and LIM WS, 2008. Ethical Planning For An Influenza Pandemic. Clinical Medicine (London, England). 8(1), 49-52